Xifaxan
Payments companies reported to CMS as associated with Xifaxan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xifaxan, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xifaxan
These are the largest totals companies reported as associated with Xifaxan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Conar Fitton | Kenner, LA | Gastroenterology (Internal Medicine) | $261,738.39 |
| Arun Jesudian | New York, NY | Hepatology | $259,730.50 |
| Apurva Modi | Rockville, MD | Gastroenterology (Internal Medicine) | $200,554.21 |
| Sammy Saab | Los Angeles, CA | Gastroenterology (Internal Medicine) | $199,041.94 |
| Ali Rezaie | West Hollywood, CA | Gastroenterology (Internal Medicine) | $183,174.74 |
| Darren Brenner | Chicago, IL | Gastroenterology (Internal Medicine) | $167,929.21 |
| Fred Fowler | Charlotte, NC | Gastroenterology (Internal Medicine) | $100,670.91 |
| Kimberly Brown | Detroit, MI | Gastroenterology (Internal Medicine) | $61,269.57 |
| Gregory Sayuk | Saint Louis, MO | Gastroenterology (Internal Medicine) | $60,559.24 |
| Jerry Martel | Miami, FL | Gastroenterology (Internal Medicine) | $58,371.07 |
Prescribed Xifaxan?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.